Back to News
Market Impact: 0.25
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
Source: globenewswire.com
Healthcare & Biotech
At ACR Convergence 2026, 5 of 6 patients (83%) with systemic sclerosis receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, and all responders maintained their response. The result is encouraging but comes from a small six-patient group.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Cabaletta Bio reports phase 1/2 data for autoimmune therapy
- Pacira’s final earnings in spotlight before $1.65B sale
- Organon earnings on deck as Sun Pharma merger awaits approval
- Street Calls of The Week
- 10 Apple products and features that transformed under Tim Cook's leadership
- CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD